Bavarian Nordic and Janssen collaborate to develop HPV vaccine

18 December 2015

Danish biotech company Bavarian Nordic (OMX: BAVA) has entered into a license and collaboration deal with Janssen Pharmaceuticals to develop a therapeutic vaccine against human papillomavirus (HPV).

Under the $171 million agreement, Janssen will acquire exclusive rights to Bavarian Nordic’s MVA-BN technology for use in a prime-boost vaccine regimen together with Janssen’s own AdVac technology.

Janssen, a division of Johnson and Johnson (NYSE: JNJ), will make an upfront payment of $9 million to Bavarian Nordic and future payments on reaching development and commercial milestones.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK